In this context, we consider the current state of therapies targeting T-cell immune checkpoint pathways and the effects of synergizing PI3K inhibition with immune checkpoint inhibitors (ICIs) to re-model the activity of T-cells and other immunosuppressive cells in the tumor microenvironment (TME). The gene discussed is PIK3CD; the disease is neoplasm.